Healthcare Services

Acute Myeloid Leukemia Market Global Report 2026 Market Expected to Record Steady Growth and Approach $5.25 Billion by 2030

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Acute Myeloid Leukemia Market At The End Of The 2026–2030 Forecast Period?

The acute myeloid leukemia market size has demonstrated substantial growth over the past few years. It is anticipated to expand from $3.73 billion in 2025 to $3.97 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. The market’s previous growth can be attributed to the rising prevalence of AML, development of hospital infrastructure, increased awareness about leukemia treatments, the adoption of traditional chemotherapy protocols, and the evolution of supportive care measures.

The market for acute myeloid leukemia is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $5.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. Factors driving this expansion during the projection period include progress in targeted therapy medications, a rise in stem cell transplantation surgeries, the creation of new tyrosine kinase inhibitors, the proliferation of ambulatory care facilities, and the incorporation of tailored medicine strategies into treatment. Key developments anticipated during this timeframe involve a greater acceptance of targeted AML treatments, an uptick in stem cell transplantation methods, increasing need for customized chemotherapy plans, the broadening availability of tyrosine kinase inhibitors and monoclonal antibodies, and a heightened emphasis on early detection and AML surveillance.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6100&type=smp

What Primary Drivers Are Shaping The Development Of The Acute Myeloid Leukemia Market?

The future expansion of the acute myeloid leukemia market is anticipated to be significantly driven by the growing integration of personalized medicine. This innovative method of healthcare and medical intervention accounts for each patient’s unique genetic makeup, environmental factors, and lifestyle. Within acute myeloid leukemia (AML), personalized medicine utilizes molecular profiling to pinpoint specific genetic mutations and biomarkers present in individual patients. This crucial data then directs the choice of targeted therapies and customized treatment strategies, enhancing the efficacy of interventions while reducing negative side effects, thus providing a more tailored and accurate approach to AML management. For example, in February 2024, the Personalised Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the rising adoption of personalized medicine is fueling the growth of the acute myeloid leukemia market.

What Segment Types Make Up The Acute Myeloid Leukemia Market?

The acute myeloid leukemia market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Stem Cell Transplant, Targeted Therapy

2) By Treatment Phase: Induction Therapy, Consolidation Therapy, Maintenance Therapy, Relapsed Or Refractory Therapy

3) By End-User: Hospitals, Specialty Oncology Centers, Transplant Centers, Research and Academic Institutes

Subsegments:

1) By Chemotherapy: Cytarabine-Based Therapy, Anthracycline-Based Therapy, Hypomethylating Agents, Low-Intensity Chemotherapy, Combination Chemotherapy Regimens

2) By Stem Cell Transplant: Allogeneic Stem Cell Transplant, Autologous Stem Cell Transplant, Conditioning Regimens, Post-Transplant Maintenance Therapy

3) By Targeted Therapy: FLT3 Inhibitors, IDH1 Inhibitors, IDH2 Inhibitors, BCL-2 Inhibitors, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, Other Targeted Agents

Which Market Trends Are Creating New Opportunities In The Acute Myeloid Leukemia Market?

Companies operating in the acute myeloid leukemia market are concentrating on developing advanced drug solutions, such as maintenance monotherapy, to broaden their product portfolios with the goal of improving patient outcomes and addressing unmet medical needs. Maintenance monotherapy refers to a medical treatment approach where a single therapeutic agent is administered to a patient as an ongoing, long-term therapy to prevent the recurrence or progression of a medical condition. For instance, in July 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for quizartinib (Vanflyta) in combination with standard cytarabine and anthracycline induction, followed by cytarabine consolidation, and as maintenance monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults with FLT3 internal tandem duplication (ITD)-positive status, as determined by an FDA-approved test. The LeukoStrat CDx FLT3 Mutation Assay has also been approved as a companion diagnostic for Vanflyta. This approval is based on positive results from the QuANTUM-First trial, demonstrating a statistically significant improvement in overall survival for patients receiving quizartinib compared to a placebo. Quizartinib’s recommended dosage varies during induction, consolidation, and maintenance phases. The drug is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation.

Who Are The Key Players Driving Competition In The Acute Myeloid Leukemia Market?

Major companies operating in the acute myeloid leukemia market are Pfizer Inc., AbbVie Inc., Novartis AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Servier Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Agios Pharmaceuticals Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Genmab AS, Aptose Biosciences Inc., Daiichi Sankyo Company Limited, BeiGene Ltd., Jazz Pharmaceuticals plc, Ipsen S.A.

Read the full acute myeloid leukemia market report here:

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

How Does The Acute Myeloid Leukemia Market Perform Across Major Global Regions?

North America was the largest region in the acute myeloid leukemia market in 2025. The regions covered in the acute myeloid leukemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Acute Myeloid Leukemia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=6100&type=smp

Browse Through More Reports Similar to the Global Acute Myeloid Leukemia Market 2026, By The Business Research Company

chronic myeloid leukemia treatment global market report

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

leqembi global market report

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

chronic myeloid leukemia treatment global market report

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795